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AbstrAct
Objective Gastric carcinoma development is triggered 
by Helicobacter pylori. Chronic H. pylori infection leads 
to reduced acid secretion, which may allow the growth 
of a different gastric bacterial community. This change in 
the microbiome may increase aggression to the gastric 
mucosa and contribute to malignancy. Our aim was to 
evaluate the composition of the gastric microbiota in 
chronic gastritis and in gastric carcinoma.
Design The gastric microbiota was retrospectively 
investigated in 54 patients with gastric carcinoma and 
81 patients with chronic gastritis by 16S rRNA gene 
profiling, using next-generation sequencing. Differences 
in microbial composition of the two patient groups were 
assessed using linear discriminant analysis effect size. 
Associations between the most relevant taxa and clinical 
diagnosis were validated by real-time quantitative PCR. 
Predictive functional profiling of microbial communities 
was obtained with PICRUSt.
results The gastric carcinoma microbiota was 
characterised by reduced microbial diversity, by 
decreased abundance of Helicobacter and by the 
enrichment of other bacterial genera, mostly represented 
by intestinal commensals. The combination of these taxa 
into a microbial dysbiosis index revealed that dysbiosis 
has excellent capacity to discriminate between gastritis 
and gastric carcinoma. Analysis of the functional features 
of the microbiota was compatible with the presence of a 
nitrosating microbial community in carcinoma. The major 
observations were confirmed in validation cohorts from 
different geographic origins.
conclusions Detailed analysis of the gastric microbiota 
revealed for the first time that patients with gastric 
carcinoma exhibit a dysbiotic microbial community 
with genotoxic potential, which is distinct from that of 
patients with chronic gastritis.
IntrODuctIOn
Gastric carcinoma is a major health problem 
worldwide, with an estimated 1 million new cases 
every year.1 Helicobacter pylori infection plays a 
crucial role in the initial steps of carcinogenesis 
by causing enhanced inflammation and progres 
sive degradation of the architecture and func-
tion of the gastric epithelium.2 3 From a certain 
point on, however, gastric carcinoma devel 
opment may be H. pylori independent, since coloni-
sation decreases (and is eventually lost) in later steps 
of carcinogenesis.4 Additionally, H. pylori eradica-
tion studies have shown that successful eradication 
does not completely prevent gastric carcinoma 
development.5–7 These observations suggest that 
factors other than H. pylori contribute to persistent 
inflammation of the gastric mucosa and to gastric 
cancer development.
It has been proposed that changes that occur in 
the stomach as a result of chronic H. pylori infec 
tion leading to decreased acid secretion allow the 
successful establishment of a new microbiota that 
contributes to malignant transformation through 
maintenance of inflammation and conversion of 
nitrates into N-nitrosamines.2 3 This is supported 
by earlier studies showing that reduction of gastric 
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significance of this study
What is already known on this subject?
 ► Helicobacter pylori infection increases the 
risk for gastric carcinoma by causing chronic 
inflammation and decreasing the number of 
acid-producing glands.
 ► Gastric acid reduction by acid-suppressive 
drugs results in bacterial overgrowth and high 
levels of gastric nitrite and N-nitrosamine.
 ► The context of a complex microbiota 
accelerates the onset and promotes neoplasia 
in the H. pylori insulin-gastrin mouse model of 
gastric cancer.
What are the new findings?
 ► The gastric microbiota profile of patients with 
carcinoma is significantly different from that of 
patients with chronic gastritis.
 ► The gastric carcinoma microbiota is dysbiotic 
and characterised by reduced microbial 
diversity, reduced Helicobacter abundance and 
over-representation of bacterial genera that 
include intestinal commensals.
 ► The microbial community found in gastric 
carcinoma has increased nitrosating functions 
consistent with increased genotoxic potential.
How might it impact on clinical practice in the 
foreseeable future?
Our results provide a new interpretative frame for 
understanding the microbial dysbiosis associated 
with gastric carcinoma, and suggest that 
alterations in the gastric microbiota may need to 
be considered to maximise efficacy of preventive 
and therapeutic strategies tailored at reducing the 
incidence of gastric carcinoma.
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acid by different types of drugs results in significant intragas-
tric bacterial overgrowth, increased counts of nitrate-reducing 
bacteria and increased nitrite and N-nitrosamine levels.8 9 This 
is further supported by studies in the hypergastrinaemic insu-
lin-gastrin (INS-GAS) transgenic mouse model, which showed 
that H. pylori-induced gastric cancer is promoted by the pres 
ence of a complex gastric microbiota, as these animals develop 
more tumours than germ-free mice infected with H. pylori 
only.10 11
So far, only a very small number of studies characterised the 
human gastric microbiota in health and disease. Their major 
findings were that H. pylori-negative subjects contained a diverse 
microbiota in their stomach, whereas in H. pylori-infected 
patients the gastric mucosa was dominated by this species.12–15 
In the context of gastric carcinogenesis, few studies have been 
conducted and no particular component of the microbiota has 
been identified as implicated in gastric carcinoma.15 16 The 
limitations of these studies are the limitations in sensitivity and 
coverage compared with more recently developed techniques, 
and, most importantly, the inclusion of very limited numbers of 
subjects, making it difficult to generate statistically significant 
conclusions. Therefore, we performed high-throughput profiling 
of the gastric bacterial communities present in 135 gastric carci-
noma cases and chronic gastritis controls, by next-generation 
sequencing (NGS) of the 16S rRNA gene. We used validation 
cohorts from multiple geographic locations to confirm our 
findings.
MAterIAls AnD MetHODs
Patients
Eighty-one individuals with chronic gastritis and 54 with 
gastric carcinoma were included in the Portuguese discovery 
cohort (see online supplementary table S1). These were part 
of a case–control study aimed at investigating risk modifiers 
for gastric cancer.17 18 Subjects with chronic gastritis (mean age 
43.6±7.0 years; male-to-female ratio 39.5:1) were recruited 
during a screening programme for premalignant lesions of the 
gastric mucosa and underwent standard gastroscopy at Centro 
Hospitalar São João (CHSJ). Eleven patients presented glan 
dular atrophy with foci of intestinal metaplasia. Of these, 1 had 
mild corpus and moderate antral atrophy and the remaining 
10 cases did not have corpus atrophy and had mild (n=6), 
moderate (n=2) or marked (n=2) atrophy in the antrum 
(including incisura). Only individuals without evidence of past 
or present peptic ulcer disease were included. In addition, 
patients under proton pump inhibitor or antimicrobial treat-
ments were excluded. Patients with gastric carcinoma (mean 
age 58.8±13.2 years; male-to-female ratio 1.5:1) were diag-
nosed and underwent cancer resection at CHSJ. A validation 
cohort of an additional 38 gastric specimens from 15 patients 
with chronic gastritis and 23 patients with gastric carcinoma, 
diagnosed between 2014 and 2016, were retrieved from the 
tissue and tumour bank at CHSJ (see online supplementary 
table S1). All procedures were in accordance with the institu-
tional ethical standards. Samples were delinked and unidenti 
fied from their donors.
Two additional validation series, consisting of NGS data of the 
16S rRNA gene of 79 gastric carcinoma cases from a population 
from China and 53 gastric carcinoma cases from a population 
from Mexico, were retrieved from the Sequence Read Archive 
(BioProject PRJNA310127; see online supplementary table 
S2).19
16s rrnA gene sequencing
DNA was isolated from gastric biop-
sies or surgical specimens of non-neo 
plastic gastric mucosa adjacent to the tumour, as previously 
described.17 The 16S rRNA gene was amplified using primers 
U789F 5′-TAGATACCCTGGTAGTCC-3′ and U1053R 
5′-CTGACGACAGCCATGC-3′ targeting the V5-V6 hyper-
variable regions and sequenced in an Ion PGM Torrent plat-
form following manufacturer’s instructions. Primers were 
designed following recommendations reported by Andersson 
et al, and were extensively analysed using PrimerProspector 
(see online supplementary figure S1).20 21
sequencing data analysis
The performance of the UPARSE pipeline was evaluated and 
compared with that reported for samples of the Human Micro-
biome Project (HMP) data set.22 Using UPARSE (usearch 
_v7.0.1090_i86linux64), reads were filtered by imposing a 
maximum number of expected errors of 0.5 and a global trim-
ming at 250 nucleotides.22 Reads were dereplicated and singletons 
were discarded. Filtered reads were clustered into operational 
taxonomic units (OTU) assuming 97% similarity. Chimeric 
reads were reference removed using Uchime.22 Each OTU was 
taxonomically assigned using Uclust considering a minimum 
percentage of similarity to a reference database (Greengenes 
Named Isolate database, release August 2013) match of 90%.23 
Diversity analyses were performed using QIIME (V.1.9).24 
Alpha diversity was determined by the Shannon index and with 
Good’s estimator of coverage. Differences in alpha diversity were 
assessed by the t-test controlled with 103 Monte Carlo permu-
tations. Beta diversity was assessed by unweighted and weighted 
UniFrac distance matrices and visualised by principal coordi-
nate analysis (PCoA), controlled by 103 jackknife replicates.25 
Sample clustering in beta diversity analysis was tested using anal-
ysis of similarity (ANOSIM) with 104 bootstrap replications.26 
Comparisons between distance matrices were evaluated by the 
Mantel correlation controlled with 104 permutations.
taxonomic discovery analysis
Statistically significant differences in the relative abundance of 
taxa associated with groups of patients were performed using 
linear discriminant analysis (LDA) effect size (LEfSe).27 Only 
taxa with LDA greater than 4 at a P value <0.05 were considered 
significantly enriched.
real-time quantitative Pcr
Sequencing results were confirmed by quantitative PCR (qPCR) 
(see online supplementary table S3).
Functional metagenome predictions
For functional metagenome prediction, we captured OTU 
representative sequences from Greengenes database using the 
USEARCH global alignment command and discarding reads 
that did not hit the reference database. Reconstruction of the 
metagenome was performed using PICRUSt.28 Accuracy of the 
predicted metagenomes was assessed by determining the nearest 
sequenced taxon index. Predicted functional genes were catego-
rised into Clusters of Orthologous Groups (COG) and into Kyoto 
Encyclopedia of Genes and Genome (KEGG) orthology (KO), 
and compared across patient groups using STAMP.29 Statistical 
differences in COG and KO frequencies were determined by 
White's non-parametric t-test with a Benjamini-Hochberg false 
discovery rate correction to adjust P values for multiple testing.30
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Figure 1 The gastric microbiota profile differs in chronic gastritis and gastric carcinoma. (A) Shannon index of diversity in patients with chronic 
gastritis and gastric carcinoma. (B) Good’s estimator of coverage, measuring the proportion of total bacterial species represented in samples of each 
group of patients. Principal coordinate analysis (PCoA) plots of (C) unweighted and (D) weighted UniFrac distances in which samples were coloured 
by clinical outcome. The percentage of diversity captured by each coordinate is shown. ANOSIM, analysis of similarity.
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For further details, see online supplementary information.
results
Quality control of 16s rrnA microbiota profiling
In the present study, we compared the gastric microbiota of 
patients with chronic gastritis with that of patients with gastric 
carcinoma by NGS of the 16S rRNA gene. After sequencing and 
quality filtering, more than 10.8 million reads were obtained 
corresponding to a mean of 80 261 reads and 178 OTUs per 
sample (see online supplementary figure S2). On average, 
patients with chronic gastritis had a significantly higher number 
of reads (86 957) than patients with cancer (67 954; P<0.05). 
However, the number of OTUs was not significantly different 
between the two patient groups (186 and 169 OTUs, respec-
tively; P=0.071). To control for the number of false OTUs and 
to measure the number of biologically meaningful OTUs, we 
classified them according to similarity shared with sequences 
of the Greengenes Named Isolated database (see online supple-
mentary figure S2). In our data set, the frequencies of misleading 
and valid OTUs were similar to those reported for the HMP 
data set processed with the UPARSE pipeline.22
To assure consistency between amplification and sequencing 
sets, 32 randomly selected samples were used to test repro-
ducibility. The intraclass correlation coefficients showed good 
reproducibility for the assessment of the Shannon index, for 
the UniFrac distances and for the relative abundance of phyla 
(see online supplementary table S4). In conclusion, our approach 
provides the most in-depth characterisation of the gastric micro-
biota so far and generates robust and consistent data.
the gastric microbiota profile differs in chronic gastritis and 
gastric carcinoma
To evaluate alterations in the microbiota structure between patients 
with chronic gastritis and gastric carcinoma, we measured micro-
bial alpha diversity (ie, within sample diversity) and beta diver-
sity (ie, diversity between samples). By measuring alpha diversity 
using the Shannon index, we found that patients with gastric carci-
noma had significantly decreased microbial diversity in compar 
ison with patients with chronic gastritis (figure 1A, P=0.003; 
online supplementary figure S3). To ensure good estimation of 
bacterial diversity, we measured the proportion of total bacte-
rial species represented in samples of each patient group by the 
Good’s estimator of coverage. Estimated coverage ranged from 
0.94 to 0.98 in chronic gastritis and from 0.95 to 0.99 in gastric 
carcinoma (P=0.225), suggesting that the 16S rRNA results from 
each (chronic gastritis and gastric carcinoma) library represent 
the majority of bacteria present in the gastric mucosa (figure 1B).
Beta diversity was calculated using both unweighted (ie, 
qualitative) and weighted (ie, quantitative) UniFrac phyloge-
netic distance matrices, and visualised in PCoA plots. The total 
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Figure 2 The influence of Helicobacter pylori in the microbiota composition of chronic gastritis and gastric carcinoma. (A) Relative abundance 
of phyla in all subjects and in each group of patients. (B) Spearman’s rank correlation between relative abundance of Helicobacter spp. and non-
Helicobacter Proteobacteria in all patients. Principal coordinate analysis (PCoA) plots of the weighted UniFrac distance matrix coloured by (C) 
increasing relative abundance of Helicobacter and of (D) non-Helicobacter Proteobacteria.
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diversity captured by the top three principal coordinates was 
29% and 47% for unweighted and weighted UniFrac, respec-
tively. The microbiota composition of patients with gastric 
carcinoma was significantly different from that of patients with 
chronic gastritis (ANOSIM R=0.406, P=0.0001; and R=0.425, 
P=0.0001, for unweighted and weighted distances, respectively; 
figure 1C,D).
Since age is an established risk factor for gastric carcinoma, 
and since patients with carcinoma were significantly older than 
patients with gastritis in our series (see online supplementary 
table S1), we next addressed whether the microbial profile 
was different between younger and older patients. Overall, 
increasing age could differentiate the microbiota profiles of 
the full sample set (see online supplementary figure S4A,B). 
However, when we performed age-matched comparisons of the 
microbiota in patients with chronic gastritis and carcinoma, we 
observed statistically significant differences in the unweighted 
and weighted UniFrac distances (see online supplementary figure 
S4C,D), reinforcing that the microbiota composition is different 
in the two clinical settings. Also in the age-matched compari-
sons, significantly decreased microbial alpha diversity was found 
in patients with gastric carcinoma (see online supplementary 
figure S4E, P=0.0096).
No statistically significant differences in the microbiota 
profiles of gastric carcinoma cases were observed for gender, 
histological type and tumour location (see online supplementary 
figure S5).
In patients with chronic gastritis, we could not detect differ-
ences in the alpha diversity and beta diversity between patients 
with non-atrophic gastritis (n=70) and patients with glandular 
atrophy (n=11; online supplementary figure S6), and therefore 
they were pooled together for the analyses.
These results show that there is a significant reduction in 
microbial diversity in gastric carcinoma. Furthermore, the 
fact that the weighted UniFrac captured more diversity than 
unweighted metrics suggests that alterations in the relative abun-
dance of taxa are a major contributor for microbiota differences 
between gastritis and gastric carcinoma.
the influence of H. pylori in the microbiota composition of 
chronic gastritis and gastric carcinoma
Overall, the gastric microbiota was dominated by five phyla: 
Proteobacteria (69.3%), Firmicutes (14.7%), Bacteroidetes 
(9.0%), Actinobacteria (4.3%) and Fusobacteria (1.3%). Although 
these phyla were present in the two patient groups in the same 
order of relative abundance, the gastric carcinoma microbiota 
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had an over-representation of Actinobacteria (P<0.001) and 
Firmicutes (P=0.040), and lower abundance of Bacteroidetes 
(P=0.003) and Fusobacteria (P<0.001; figure 2A).
When reads assigned to Proteobacteria into Helicobacter spp. 
and non-Helicobacter Proteobacteria were separated, a signifi-
cant reduction in the abundance of Helicobacter (P<0.001) and 
an over-representation of non-Helicobacter Proteobacteria were 
detected in gastric carcinoma (P<0.001; figure 2A). Accordingly, 
a significant negative correlation was found between these taxa 
(r=−0.53, P<0.0001; figure 2B). In support of the above, the 
microbiota profile of the two patient groups could be distin-
guished by the abundance of Helicobacter (Mantel correla-
tion, r=0.313, P=0.001; figure 2C) and by the abundance of 
non-Helicobacter Proteobacteria (Mantel correlation, r=0.447, 
P=0.001; figure 2D).
Regarding Helicobacter spp. in chronic gastritis, the mean 
relative abundance of this genus was 41.7%, but varied consid-
erably between patients from 0.01% to 94.9% (figure 2A). The 
relative abundance of Helicobacter was inversely correlated with 
the abundance of non-Helicobacter Proteobacteria (r=−0.59, 
P<0.0001), Firmicutes (r=−0.49, P<0.0001), Bacteroi-
detes (r=−0.43, P<0.0001) and Actinobacteria (r=−0.54, 
P<0.0001; online supplementary table S5). In contrast, the great 
majority of patients with gastric carcinoma (80%) had a relative 
abundance of Helicobacter below 5%, including eight patients in 
which Helicobacter reads were not detected by NGS. The abun-
dance of Helicobacter in gastric carcinoma was correlated with 
that of Bacteroidetes and Fusobacteria (see online supplementary 
table S5).
Overall, these results show that for high taxonomic levels the 
stomach microbial communities differ in chronic gastritis and 
gastric carcinoma, suggesting that major changes also occur 
at lower taxonomic levels. Additionally, our data validate that 
Helicobacter exists in the gastric carcinoma microbiota as a low 
abundant or absent genus.
specific microbial taxa are associated with gastric carcinoma
To identify the most relevant taxa responsible for the differences 
between clinical diagnoses, we conducted LEfSe analysis.27 This 
analysis identified 29 taxa, including 10 genera, which were 
differentially abundant in the two patient groups (figure 3A,B). 
In gastric carcinoma, an enrichment in Proteobacteria taxa was 
observed, including the genera Phyllobacterium and Achromo-
bacter and the families Xanthomonadaceae and Enterobacte-
riaceae. Although no specific genus could be identified within 
the Xanthomonadaceae, in the Enterobacteriaceae, the genus 
Citrobacter was identified as being significantly enriched in 
gastric carcinoma. Additionally, Lactobacillus, Clostridium and 
Rhodococcus were also significantly more abundant in gastric 
carcinoma. Helicobacter, Neisseria, Prevotella and Streptococcus 
were most abundant in the microbiota of patients with chronic 
gastritis. Results of the LEfSe analysis in the age-matched subset 
closely recapitulated the bacteria taxa differentially abundant in 
the two patient groups (see online supplementary figure S4F).
To show that relationships among disease-associated taxa did 
not depend on differences observed in the abundance of Helico-
bacter, we conducted a reanalysis subtracting the Helicobacter 
reads from the data set. Considering the same parameters in the 
LEfSe analysis, we confirmed the enrichment of Streptococcus, 
Prevotella and Neisseria in chronic gastritis (see online supple-
mentary figure S7). Additionally, we identified an enrichment 
in two Proteobacteria taxa, Novosphingobium and Pasteurel-
lales, and in two Bacteroidetes families, Chitinophagaceae and 
Saprospirae. In gastric carcinoma, no additional taxa were 
detected after removing the Helicobacter reads from the data set.
To validate gastric carcinoma-enriched and depleted taxa, 
we used NGS data from an independent Chinese cohort of 79 
gastric carcinoma cases. In this data set, and in agreement with 
the results obtained in the Portuguese discovery cohort, we 
could detect statistically significant enrichment in Citrobacter, 
Rhodococcus, Lactobacillus and Phyllobacterium, and depletion 
in Helicobacter and Neisseria (figure 3C). Clostridium reads 
were enriched in gastric carcinoma cases from the Chinese popu-
lation, although not reaching statistical significance in the LEfSe 
analysis. Achromobacter reads were not detected in the Chinese 
validation cohort.
To demonstrate that our data were not biased by the micro-
biota profiling pipeline used, LEfSe results were validated by 
qPCR in the Portuguese discovery cohort using both genus-spe-
cific and universal primers. We confirmed significant decreases 
in the abundance of Helicobacter and Neisseria, and significant 
increases of Achromobacter, Citrobacter, Phyllobacterium, Clos-
tridium, Rhodococcus and Lactobacillus in gastric carcinoma in 
comparison with chronic gastritis (figure 3D). We have addition-
ally used a second validation cohort from Portugal, and with 
the exception of Prevotella and Streptococcus, we were able to 
confirm the alterations in the abundance of the eight genera as 
identified by the original LEfSe analysis (figure 3E).
Next, we compared gastric carcinoma cases and chronic 
gastritis control subjects for the prevalence of specific taxa. As 
shown in table 1, the six genera significantly enriched in gastric 
carcinoma and identified by LEfSe analysis were also signifi-
cantly more prevalent in patients with gastric carcinoma than 
in patients with chronic gastritis. In logistic regression models 
with carriage of the genera Phyllobacterium, Achromobacter, 
Citrobacter, Lactobacillus, Clostridium or Rhodococcus as the 
independent variables, and gastric carcinoma as the dependent 
variable, the ORs for gastric carcinoma were 3.5 (95% CI 1.7 to 
7), 20.5 (95% CI 7.4 to 59), 9.9 (95% CI 4.3 to 23), 6.3 (95% 
CI 2.9 to 14), 5.7 (95% CI 2.2 to 15) and 4.2 (95% CI 1.7 to 11), 
respectively. The associations remained significant after adjust-
ment for age and sex.
Microbial dysbiosis is associated with gastric carcinoma
We next combined the 10 most relevant taxa that characterised 
each group of patients and calculated the microbial dysbiosis 
index (MDI).31 The gastric microbiota of patients with gastric 
carcinoma had a higher MDI than that of patients with chronic 
gastritis both in the discovery cohort and in the validation cohorts 
(P<0.0001; figure 4A). Similar findings were observed in the 
age-matched subset of the discovery cohort (see online supple-
mentary figure S4G). Likewise, significantly higher MDI was 
observed in the microbiota of patients with gastric carcinoma 
in comparison with that of patients with chronic gastritis, 
as assessed using qPCR in the Portuguese validation cohort 
(P<0.0001; figure 4B). The MDI showed an inverse correlation 
with the alpha diversity (r=−0.262, P=0.005; figure 4C) and 
a direct correlation with the beta diversity (r=0.208, P=0.001; 
figure 4D), resulting in a clear differentiation gradient among 
samples. These results demonstrate that the gastric carcinoma 
microbiota has a high degree of dysbiosis, consistent with 
reduced bacterial diversity.
We also evaluated whether the MDI could be used to 
discriminate between chronic gastritis and gastric carci-
noma. In receiver operating characteristics (ROC) analysis, 
the MDI showed excellent performance in identifying gastric 
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Figure 3 Microbial taxa associated with gastric carcinoma. (A) Cladogram representation of the gastric microbiota taxa associated with chronic 
gastritis and gastric carcinoma. (B) Association of specific microbiota taxa with the group of chronic gastritis and gastric carcinoma by linear 
discriminant analysis (LDA) effect size (LEfSe). Green indicates taxa enriched in chronic gastritis group and red indicates taxa enriched in gastric 
carcinoma group. (C) Relative abundance of the 10 genera differentially enriched in the two clinical settings across Portuguese discovery and Chinese 
validation cohorts. *Significance obtained by LEfSe analysis at P<0.05. (D,E) Validation of LEfSe results by quantitative PCR (qPCR) of the 10 genera 
differentially enriched in the discovery cohort (D) and in the Portuguese validation cohort (E). Significance was obtained by Student’s t-test.
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carcinoma, yielding an area under the curve (AUC) of 0.91 
and 0.89 for the Portuguese discovery and validation cohorts, 
respectively (figure 4E,F). The MDI exhibited improved 
sensitivity and specificity to detect gastric carcinoma when 
compared with the use of single taxa (see online supplementary 
figure S8).
Since in the validation cohorts we could not confirm the 
differential abundance of Prevotella and Streptococcus, we 
recalculated the MDI excluding these genera. This analysis 
confirmed higher levels of dysbiosis in the gastric carcinoma 
microbiota in all cohorts, and similar AUCs in the ROC analysis 
(see online supplementary figure S9).
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stomach
the gastric carcinoma microbiota is characterised by 
nitrosating bacteria
To infer the metagenome functional content based on the 
microbial community profiles obtained from the 16S rRNA 
gene sequences we used PICRUSt.28 Overall, the microbial 
communities present in patients with gastric carcinoma and 
chronic gastritis could be distinguished based on their functions 
(see online supplementary figure S10A). The predicted KEGG 
pathways significantly enriched in gastric carcinoma included 
membrane transport, carbohydrate metabolism, transcription, 
xenobiotics biodegradation and metabolism, cellular processes 
and signalling, metabolism, signal transduction, amino acid 
metabolism and lipid metabolism (see online supplementary 
table S6).
Because it has been hypothesised that nitrate-reducing bacte-
rial species contribute to gastric malignant transformation by 
increasing intragastric concentrations of nitrite and N-nitroso 
compounds, we next compared chronic gastritis and gastric 
carcinoma regarding the microbial functional features involved 
in those metabolic reactions (see online supplementary table 
S7). The full reconstitution of the metagenomes showed that the 
functional composition of the total gastric carcinoma microbiota 
had increased nitrate reductase functions, which promote the 
reduction of nitrate to nitrite, and nitrite reductase functions, 
which promote the reduction of nitrite to nitric oxide, when 
compared with that of the chronic gastritis (figure 5A,B). Similar 
results were obtained when the 10 genera differentially abundant 
in the two patient groups were analysed (see online supplemen-
tary figure S10B,E). Collectively, these data provide evidence 
that a microbial community with genotoxic potential is present 
in gastric carcinoma.
DIscussIOn
We have profiled the gastric microbiota associated with chronic 
gastritis and gastric carcinoma in the largest and most in-depth 
study to date. We have demonstrated that the gastric microbiota 
composition in patients with gastric carcinoma is significantly 
different from that of patients with chronic gastritis. Gastric 
carcinoma dysbiosis was consistent with a microbial community 
with genotoxic potential, characterised by reduced microbial 
diversity, reduced Helicobacter abundance and over-representa-
tion of new bacterial genera. The major findings revealed in the 
Portuguese discovery cohort were confirmed in additional vali-
dation cohorts from multiple geographic locations.
In our study, the gastric microbial communities in gastritis 
and carcinoma were structurally different, with decreased 
alpha diversity in carcinoma. Our findings are supported by 
previous data pointing to lower bacterial diversity among five 
patients with gastric cancer compared with five patients with 
non-atrophic gastritis.15 Also supporting our data, and while our 
paper was in revision, another paper was published in Gut that 
identified significant decreases in microbial richness in intestinal 
metaplasia and in gastric carcinoma compared with superficial 
gastritis.32 Reduced microbial diversity has now been recognised 
as a feature of disease states, including inflammatory diseases 
and cancer.31 33 34 For example, patients with colorectal cancer 
had decreased overall microbial community diversity in compar-
ison to healthy controls.34
In terms of the composition of the gastric microbiota, Proteo-
bacteria, Firmicutes, Bacteroidetes, Actinobacteria and Fusobac-
teria were the five dominant phyla in the stomach, in accordance 
with previous descriptions.12 14 20 At the phylum level, we have 
already identified differences between the two patient groups, 
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Figure 4 Microbial dysbiosis is associated with gastric carcinoma. (A) Box plot showing the MDI in the discovery cohort and in the Chinese 
and Mexican validation cohorts. Significance was obtained by one-way analysis of variance (ANOVA) corrected with Holm-Sidak test for multiple 
comparisons. (B) Box plot showing the MDI of the Portuguese validation cohort. Significance was obtained by Student’s t-test. (C) Negative Pearson’s 
correlation between MDI and Shannon index. (D) Principal coordinate analysis (PCoA) plot of the weighted UniFrac distance coloured by increasing 
MDI. The percentage of diversity captured by each coordinate is shown. Mantel correlations controlled with 104 permutations were used to compare 
distances. (E,F) ROC curves analysis to evaluate the discriminatory potential of MDI in gastric carcinoma detection in the discovery cohort (E) and in 
the Portuguese validation cohort (F). AUC, area under the curve; MDI, microbial dysbiosis index; ROC, receiver operating characteristic.
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with increased abundance of non-Helicobacter Proteobacteria, 
Firmicutes and Actinobacteria in cancer specimens. Importantly, 
by applying the LEfSe algorithm that was validated for high-di-
mensional microbiome data sets, we were able to determine the 
bacterial taxa that most likely explain differences between clin-
ical diagnoses.27 Additionally, in this study, the major taxonomic 
differences that were detected after analyses of sequencing-gen-
erated and bioinformatics-treated data were further validated by 
real-time qPCR assays.
In chronic gastritis, and as expected, Helicobacter was 
detected as the most abundant genus. Streptococcus, Prevotella 
and Neisseria were also found significantly overabundant 
in this patient group, although Streptococcus and Prevotella 
could not be confirmed by qPCR. Nevertheless, these genera 
have been identified earlier in H. pylori-positive and negative 
gastritis by 16S rDNA and rRNA sequencing, and by culture 
from gastric juice and gastric biopsies.12 14 35 36 In fact, they are 
among the five most commonly found genera in the non-neo-
plastic stomach.12 20 37Streptococcus, Prevotella and Neisseria 
are commensals of the oral cavity and oesophagus and whether 
they constitute transient or active resident stomach microbes 
is not yet clarified. Interestingly, in a study that compared the 
gastric microbiota compositions in H. pylori-positive individuals 
from two populations with high and low gastric cancer risks in 
Colombia, Neisseria and Streptococcus were among the genera 
that occurred more abundantly in individuals from the low 
gastric cancer risk region.38
In gastric carcinoma, there was a significant decrease in Heli-
cobacter abundance, and several taxa were found to be signifi-
cantly more abundant. These included Citrobacter, Clostridium, 
Lactobacillus, Achromobacter and Rhodococcus, which reside 
in the intestinal mucosa as commensals but can be opportu-
nistic pathogens.39 40 Phyllobacterium, which are environmental 
bacteria commonly found in plant roots, were too identified at 
higher abundance in gastric carcinoma.41 All genera significantly 
overabundant in gastric carcinoma were also significantly more 
prevalent in gastric carcinoma cases than in chronic gastritis 
control patients, and these associations remained significant 
after adjustment for age and sex. In line with our results, in a 
study that combined terminal restriction fragment length poly-
morphism with 16S rRNA gene cloning and sequencing, Lacto-
bacillus was one of the dominating genera in 10 Swedish patients 
with gastric cancer.16 Additionally, the use of the microarray G3 
PhyloChip to characterise the stomach microbiota of Mexican 
patients revealed a trend towards the increase of a Lactoba-
cillus sp from non-atrophic gastritis, to intestinal metaplasia, to 
gastric cancer.15 Moreover, Citrobacter, Clostridium and Lacto-
bacillus have all been cultured from the gastric juice of achlo-
rhydric patients, patients undergoing acid suppression therapy 
and patients with gastric cancer.42–44 Interestingly, infection with 
Citrobacter rodentium species increases epithelial cell prolifer-
ation and promotes colonic tumour formation in genetically 
susceptible mice as well as in chemically initiated colon carcino-
genesis.45 46
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Figure 5 The gastric carcinoma microbiota is characterised by nitrosating bacteria. Functional classification of the predicted metagenome content 
of the microbiota of chronic gastritis and gastric carcinoma using (A) COG and (B) KO. The normalised relative frequency of nitrate reductase and 
nitrite reductase in patients with chronic gastritis and gastric carcinoma is shown. Significance was considered for adjusted P<0.05. COG, Clusters of 
Orthologous Groups; KO, Kyoto Encyclopedia of Genes and Genome (KEGG) orthology; NADH, nicotinamide adenine dinucleotide; NO, nitric oxide; 
TMAO, trimethylamine N-oxide.
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The integration of data from the most relevant genera that 
characterised each patient group allowed us to calculate the 
dysbiosis index that showed excellent capacity to discrimi-
nate between gastritis and gastric carcinoma. Furthermore, 
the dysbiosis index had improved sensitivity and specificity to 
detect gastric carcinoma in comparison with the use of single 
genera, which suggests that changes in the microbial commu-
nity rather than individual taxa contribute to gastric carcinoma 
development.
After having analysed the diversity and composition of the 
gastric microbiota and the microbial features associated with 
gastric carcinoma, we addressed the functional features of 
the microbiota. Specifically, we demonstrated that in compar-
ison with chronic gastritis, the gastric carcinoma microbiota 
has increased nitrate reductase and nitrite reductase functions. 
This observation is compatible with the hypothesis that during 
carcinogenesis, changes in the stomach mucosa that lead to 
decreased acid secretion allow the growth of bacteria that are 
able to reduce nitrate to nitrite, a precursor of carcinogenic 
N-nitroso compounds.2
Taken together our results and previously published data, 
we propose that colonisation with bacteria other than H. 
pylori, namely gut commensals, contributes to alter the equi-
librium between the ‘resident’ gastric microbiota and the host. 
This dysbiotic microbial community, by sustaining the gastric 
inflammatory process, and through its intrinsic genotoxic 
potential, may augment the risk for H. pylori-related gastric 
carcinoma development. In line with our proposal, experi-
mental evidence in the INS-GAS model showed that commensal 
intestinal bacteria play a role in the promotion of gastric 
cancer.12 13 Lertpiriyapong et al showed that mice harbouring 
a complex intestinal microbiota, and mice colonised with a 
restricted intestinal microbiota (that includes Clostridium and 
Lactobacillus), had an accelerated onset and progression of 
gastric cancer secondary to H. pylori infection. These mice 
also developed more severe gastric histopathology and higher 
expression levels of proinflammatory genes in comparison 
to germ-free mice (infected or not with H. pylori) and mice 
harbouring a complex or a restricted intestinal microbiota.11
Although our study is limited by its retrospective nature, and 
by the low number of patients with true premalignant lesions, 
our findings are consistent with a shift in the gastric micro-
bial community structure along gastric carcinogenesis. In this 
sense, prospective follow-up studies of patients with prema-
lignant lesions, successfully eradicated or not for H. pylori 
infection, would be crucial to ascertain the pathogenic effect 
of microbial dysbiosis in the progression to carcinoma. Addi-
tional studies to address the effect of dysbiosis or of candidate 
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bacterial species in an animal model of gastric carcinogen-
esis can also be considered, and in that regard, a humanised 
mouse model that better mimics the human immune response 
could be particularly informative. Ultimately, understanding 
the microbiota dynamics along gastric carcinogenesis may 
impact gastric carcinoma prevention and treatment strategies 
of patients with precancerous disease.
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